Eli Lilly and Company $LLY Shares Sold by Private Capital Advisors Inc.

Private Capital Advisors Inc. reduced its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 1.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 427,503 shares of the company’s stock after selling 6,132 shares during the quarter. Eli Lilly and Company accounts for about 46.9% of Private Capital Advisors Inc.’s holdings, making the stock its biggest position. Private Capital Advisors Inc.’s holdings in Eli Lilly and Company were worth $459,429,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the business. Vanguard Group Inc. grew its holdings in shares of Eli Lilly and Company by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock valued at $88,087,193,000 after buying an additional 1,006,885 shares during the last quarter. State Street Corp grew its holdings in shares of Eli Lilly and Company by 0.6% during the third quarter. State Street Corp now owns 34,726,558 shares of the company’s stock valued at $26,496,364,000 after buying an additional 219,590 shares during the last quarter. Capital Research Global Investors grew its holdings in shares of Eli Lilly and Company by 20.9% during the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock valued at $19,141,787,000 after buying an additional 4,332,008 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Eli Lilly and Company by 4.1% during the third quarter. Wellington Management Group LLP now owns 14,563,780 shares of the company’s stock valued at $11,112,164,000 after buying an additional 574,229 shares during the last quarter. Finally, Capital International Investors grew its holdings in shares of Eli Lilly and Company by 6.1% during the third quarter. Capital International Investors now owns 10,001,509 shares of the company’s stock valued at $7,628,447,000 after buying an additional 579,381 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently issued reports on LLY. Truist Financial reiterated a “buy” rating on shares of Eli Lilly and Company in a report on Monday, February 23rd. Royal Bank Of Canada restated an “outperform” rating on shares of Eli Lilly and Company in a report on Thursday. Rothschild & Co Redburn boosted their price target on shares of Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Freedom Capital upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 10th. Finally, Wells Fargo & Company boosted their price target on shares of Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $1,220.37.

Eli Lilly and Company Stock Up 2.4%

Eli Lilly and Company stock opened at $1,066.59 on Friday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The stock has a market cap of $1.00 trillion, a PE ratio of 37.89, a price-to-earnings-growth ratio of 1.16 and a beta of 0.48. The firm’s 50-day simple moving average is $942.87 and its 200 day simple moving average is $1,003.77. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. During the same period in the previous year, the company earned $3.34 earnings per share. The firm’s revenue for the quarter was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Research analysts predict that Eli Lilly and Company will post 35.82 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be given a $1.73 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s payout ratio is currently 24.58%.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Goldman Sachs reaffirmed its Buy rating on LLY and raised its price target to $1,283, signaling confidence in further upside. MarketScreener Latest Ratings
• Positive Sentiment: Jefferies lifted its price target on Eli Lilly to $1,330, also implying meaningful upside from recent trading levels. MarketScreener
• Positive Sentiment: New clinical updates across Lilly’s pipeline, including positive obesity conference data, Alzheimer’s study progress, and a new heart-failure trial, help reinforce the market’s view that Lilly has multiple growth drivers beyond its current diabetes and obesity drugs.
• Neutral Sentiment: Lilly also announced an acquisition of Engage Biologics, extending its gene-therapy ambitions; this supports long-term diversification, but the near-term stock impact is less direct. Eli Lilly’s Engage Biologics Deal Extends Genetic Bets Beyond Obesity Boom

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.